Advantage Alpha Capital Partners LP Reduces Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Advantage Alpha Capital Partners LP trimmed its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 20.8% in the 4th quarter, HoldingsChannel reports. The firm owned 69,182 shares of the biotechnology company’s stock after selling 18,209 shares during the quarter. Advantage Alpha Capital Partners LP’s holdings in ADMA Biologics were worth $1,186,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. State Street Corp increased its holdings in ADMA Biologics by 61.4% in the 3rd quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock worth $259,970,000 after buying an additional 4,945,063 shares during the period. Perpetual Ltd purchased a new position in shares of ADMA Biologics during the fourth quarter worth $62,300,000. Lord Abbett & CO. LLC acquired a new position in ADMA Biologics during the third quarter valued at $61,858,000. Allspring Global Investments Holdings LLC boosted its holdings in ADMA Biologics by 1,144.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock valued at $51,016,000 after purchasing an additional 2,613,482 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in ADMA Biologics during the 4th quarter worth about $19,076,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Stock Up 0.8 %

ADMA stock opened at $19.80 on Monday. The firm’s fifty day moving average is $16.76 and its 200 day moving average is $18.05. The firm has a market cap of $4.68 billion, a PE ratio of 70.71 and a beta of 0.60. ADMA Biologics, Inc. has a one year low of $5.90 and a one year high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 target price on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.